Principal Investigator
Professor of Bioscience
Current
B2/L4 - 4219
Social Profile:
Professor Hauser’s research interests align at the interfaces between chemistry, biomedicine, bioengineering and nanotechnology. Focus is on the development of platform technologies, using smart nanomaterials for regenerative, biomedical and environmental applications.
Her interest refers to the rational molecular design, synthesis and mechanistic understanding of novel supramolecular structures. Investigated systems include peptide-based nanostructures with an innate propensity to self-assemble to biomimetic architectures applicable for biomedical applications such as cell substrates, sensors and 3D tissue scaffolds for regenerative medicine. Bottom-up nanofabrication is a powerful tool for the development of functional tissue equivalents, organotypic tissues and devices. Moreover, these biomimetic supramolecular constructs will be used for the design and fabrication of novel organ-on-a-chip devices and disease models. Furthermore, Professor Hauser is interested in 3D bioprinting, using supramolecular organotypic constructs to fabricate high-throughput platforms for drug screening, pathogen detection and other diagnostic purposes. Synthetic biology approaches are explored for the generation of functional biomaterial.
Charlotte A.E. Hauser is a Professor of Bioengineering, Bioscience and Material Science at King Abdullah University of Science and Technology (KAUST) and the Chair of the Bioengineering Program. Before joining KAUST, she was a Principal Investigator at the Institute of Bioengineering and Nanotechnology, A*Star, Singapore, and Adjunct Professor at Nanyang Technological University (NTU), Singapore. Her invention of ultrashort peptide-based wound healing nanogels ranked first in 2015 on the innovation list of “Asian Biotech”. Together with her partner Octapharma, a Swiss pharmaceutical company, for almost 10 years, she was founder and CEO of Theragene/Octagene in Munich/Martinsried, Germany, where she developed the first truly human recombinant coagulation factor VIII (hFVIII), approved in 2014 by FDA, EMEA and other regulatory authorities under the trade name of NUWIQ®. Nuwiq has reached several billions of revenues in sales. Her honors and awards include awards from the German Federal Ministry of Science and Technology, France’s Société des Amis des Sciences, and Bavarian Research Foundation. She filed over fifty U.S. patents of which the majority got licensed to Nestle Skin Health, Octapharma AG, 3-D Matrix Co. Ltd., and PepNano.
Her current focus is on a unique class of self-assembling ultrashort peptide nanogels as a platform for 3D organ and tissue fabrication for personalized treatment regimes. In addition, she approaches to improve major environmental damages such as coral bleaching and reef reconstruction with sustainable and eco-friendly materials and high-end technologies of 3D robotic printing. Prof. Hauser is a Fellow of the American Institute for Medical and Biological Engineers (AIMBE) and since 2015 a Fellow of the US National Academy of Inventors (NAI). She is Associate Editor of several academic journals. Her research includes molecular self-assembly, ultrashort synthetic peptides, synthetic biomaterials, nanogels, tissue engineering, personalized regenerative therapies, 3D robotic printing/bioprinting and eco-friendly, sustainable environmental regeneration.
"KAUST shall be a beacon for peace, hope and reconciliation, and shall serve the people of the Kingdom and the world."
King Abdullah bin Abdulaziz Al Saud, 1924 – 2015
Thuwal 23955-6900, Kingdom of Saudi Arabia
Al-Haytham Building (Bldg. 2)
© King Abdullah University of Science and Technology. All rights reserved